Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks -- Ignore unavailable to you. Want to Upgrade?

To: Cogito Ergo Sum who wrote (48869)	2/28/2019 5:00:29 PM
From: russet	Read Replies (1) \| Respond to of 49402

That is another competitive process to cannabis growing. Yeast can make many of the active chemicals in weed and the chemicals can be extracted cheaper. But what other companies and researchers are doing is starting from simpler chemicals and creating THC and CBD's in the lab through chemical processes. Like making diamonds from carbon in machines rather than digging them up and extracting them from rock. No living organisms needed. Watch CRDL. CardiolRx Pharmaceutical Cannabidiol In collaboration with Dalton Pharma Services, Cardiol is developing unique manufacturing expertise in the production of pharmaceutical cannabinoids in support of its nanotherapeutics program in heart failure. With the de-scheduling of cannabinoids from the federal Controlled Drugs and Substances Act, Cardiol believes there is a significant opportunity to manufacture and commercialize pure pharmaceutical cannabidiol regulated by the federal Cannabis Act. • FDA/Health Canada certified cGMP manufacturer • Pharmaceutical cannabidiol • Precise dosing • >99.5% purity • THC Free (less than 10 ppm) New Frontier Data estimates that annual sales in Canada of medicinal cannabinoids in 2017 exceeded $600 million and forecasts sales to reach $1.2 billion in 2018. Cardiol believes that a pharmaceutical cannabidiol product, which will address a significant proportion of the total medicinal cannabinoid market, manufactured by a Health Canada regulated/FDA registered cGMP facility, will have key competitive advantages regarding traceability, dosimetry, consistency, and purity. Cardiol also believes this new class of cannabidiol-based products will provide the Company with a significant near-term revenue opportunity.